Aug 12, 2018

ResTORbio Announces Results in Phase 2b Human Trial

Posted by in categories: biotech/medical, life extension

#mTOR (mammalian target of rapamycin) Inhibiting TORC1 has been shown to increase lifespan.

Today, we are pleased to announce that the results are in from a human trial that targets the aging immune system and that an immune system-boosting drug appears to be effective.

Targeting TORC1 to boost the immune system

As we age, the immune system becomes increasingly poor and unable to detect and fight infections. This can make the elderly vulnerable to respiratory tract infections (RTIs), thus impacting their health and quality of life and leaving them at risk of dying from such infections. There are currently no treatments for RTIs that target the aging immune system directly.

Read more

Comments are closed.